Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
复制标题
DOI：
10.1001/archgenpsychiatry.2010.116
复制
发表时间：
2011-01-01
影响因子：
--
通讯作者：
Greer, George R.
中科院分区：
文献类型：
--
作者：
Grob, Charles S.;Danforth, Alicia L.;Greer, George R.
背景：研究人员在20世纪50年代和60年代对致幻剂进行了广泛的调查。然而，到了20世纪70年代初，政治和文化压力迫使所有项目停止。本研究重新审视了致幻剂在治疗晚期癌症反应性焦虑中潜在的有前景的临床应用。目的：探讨裸盖菇素治疗晚期癌症伴反应性焦虑患者的安全性和有效性。设计：一项针对患有晚期癌症和焦虑症的患者的双盲、安慰剂对照研究，受试者作为自己的对照，使用中等剂量（0.2 mg/kg）的裸盖菇素。设置：大型公共部门学术医疗中心内的临床研究单位。参与者：12名患有晚期癌症和焦虑症的成年人。主要结果测量：除了在实验治疗之前和期间监测安全性和主观体验外，在治疗后6个月，以非盲方式收集随访数据，包括Beck抑郁量表、情绪状态概况和状态-特质焦虑量表的结果。裸盖菇素没有临床显著的不良事件。状态-特质焦虑量表特质焦虑子量表显示治疗后1个月和3个月焦虑显著降低。贝克抑郁症量表显示，改善情绪，达到显着的6个月的情绪状态的配置文件确定的情绪改善后，治疗与psilocybin接近，但没有达到significance.Conclusions：这项研究建立了管理的可行性和安全性的中等剂量的psilocybin晚期癌症和焦虑的患者。一些数据显示出改善情绪和焦虑的积极趋势。这些结果支持了在这个长期被忽视的领域进行更多研究的必要性。
Context: Researchers conducted extensive investigations of hallucinogens in the 1950s and 1960s. By the early 1970s, however, political and cultural pressures forced the cessation of all projects. This investigation reexamines a potentially promising clinical application of hallucinogens in the treatment of anxiety reactive to advanced-stage cancer.Objective: To explore the safety and efficacy of psilocybin in patients with advanced-stage cancer and reactive anxiety.Design: A double-blind, placebo-controlled study of patients with advanced-stage cancer and anxiety, with subjects acting as their own control, using a moderate dose (0.2 mg/kg) of psilocybin.Setting: A clinical research unit within a large public sector academic medical center.Participants: Twelve adults with advanced-stage cancer and anxiety.Main Outcome Measures: In addition to monitoring safety and subjective experience before and during experimental treatment sessions, follow-up data including results from the Beck Depression Inventory, Profile of Mood States, and State-Trait Anxiety Inventory were collected unblinded for 6 months after treatment.Results: Safe physiological and psychological responses were documented during treatment sessions. There were no clinically significant adverse events with psilocybin. The State-Trait Anxiety Inventory trait anxiety subscale demonstrated a significant reduction in anxiety at 1 and 3 months after treatment. The Beck Depression Inventory revealed an improvement of mood that reached significance at 6 months; the Profile of Mood States identified mood improvement after treatment with psilocybin that approached but did not reach significance.Conclusions: This study established the feasibility and safety of administering moderate doses of psilocybin to patients with advanced-stage cancer and anxiety. Some of the data revealed a positive trend toward improved mood and anxiety. These results support the need for more research in this long-neglected field.